Panion’s presentation at the investor meeting 14. December 2018

The CEO of Panion, Anja Holm, presented the progress and the plans for the company’s development at the investor meeting held at Mangold offices in relation with the current share issue. Panion’s epilepsy project has just started the clinical phase with a pilot study...

Panion starts clinical study in dogs

Panion Animal Health AB develops a novel gene therapy treatment for dogs with epilepsy. The first clinical trial will be conducted at Long Island Veterinary Specialists, Ophthalmology, Surgery, Internal Medicine, Emergency, PLLC (“LIVS”) in New York, USA. It is a...

Final dog study results

Panion Animal Health AB develops a new gene therapy treatment for dogs with epilepsy, based on CombiGene’s vector that is in development for humans. Read the...

Memorandum Published/Memorandum publicerat

Investment Memorandum – The Board of Panion Animal Health AB (publ) publishes the invitation to subscribe for shares in the Company. Subscription period: December 7, 2018 – December 21, 2018 Subscription price: SEK 1 per share. Press release>> Memorandum>>  ...